Articles with public access mandates - Antonio PalumboLearn more
Not available anywhere: 3
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
S Amorim, A Stathis, M Gleeson, S Iyengar, V Magarotto, X Leleu, ...
The Lancet Haematology 3 (4), e196-e204, 2016
Mandates: National Institute for Health Research, UK
Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders
M Ladetto, M Brüggemann, L Monitillo, S Ferrero, F Pepin, D Drandi, ...
Leukemia 28 (6), 1299-1307, 2014
Mandates: Government of Italy
Development of a clinical prediction rule for venous thromboembolism in patients with acute leukemia
F Al-Ani, YP Wang, A Lazo-Langner
Thrombosis and Haemostasis 120 (02), 322-328, 2020
Mandates: Canadian Institutes of Health Research
Available somewhere: 58
Revised international staging system for multiple myeloma: a report from International Myeloma Working Group
A Palumbo, H Avet-Loiseau, S Oliva, HM Lokhorst, H Goldschmidt, ...
Journal of clinical oncology 33 (26), 2863-2869, 2015
Mandates: US National Institutes of Health
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
SV Rajkumar, JL Harousseau, B Durie, KC Anderson, M Dimopoulos, ...
Blood, The Journal of the American Society of Hematology 117 (18), 4691-4695, 2011
Mandates: US National Institutes of Health
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and …
RA Kyle, BGM Durie, SV Rajkumar, O Landgren, J Bladé, G Merlini, ...
Leukemia 24 (6), 1121-1127, 2010
Mandates: US National Institutes of Health
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study
SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ...
Leukemia 26 (1), 149-157, 2012
Mandates: US National Institutes of Health
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis
F Pichiorri, SS Suh, M Ladetto, M Kuehl, T Palumbo, D Drandi, C Taccioli, ...
Proceedings of the National Academy of Sciences 105 (35), 12885-12890, 2008
Mandates: US National Institutes of Health
Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis
PL McCarthy, SA Holstein, MT Petrucci, PG Richardson, C Hulin, P Tosi, ...
Journal of Clinical Oncology 35 (29), 3279-3289, 2017
Mandates: US National Institutes of Health
Proteasome inhibitors in multiple myeloma: 10 years later
P Moreau, PG Richardson, M Cavo, RZ Orlowski, JF San Miguel, ...
Blood, The Journal of the American Society of Hematology 120 (5), 947-959, 2012
Mandates: US National Institutes of Health
RETRACTED: downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development
F Pichiorri, SS Suh, A Rocci, L De Luca, C Taccioli, R Santhanam, ...
Cancer cell 18 (4), 367-381, 2010
Mandates: US National Institutes of Health, Fondazione Telethon, Italy, Cancer Research UK
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
C Fernández de Larrea, RA Kyle, BGM Durie, H Ludwig, S Usmani, ...
Leukemia 27 (4), 780-791, 2013
Mandates: US National Institutes of Health, Government of Spain
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation
M Cavo, SV Rajkumar, A Palumbo, P Moreau, R Orlowski, J Bladé, ...
Blood, The Journal of the American Society of Hematology 117 (23), 6063-6073, 2011
Mandates: US National Institutes of Health
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2
NC Munshi, KC Anderson, PL Bergsagel, J Shaughnessy, A Palumbo, ...
Blood, The Journal of the American Society of Hematology 117 (18), 4696-4700, 2011
Mandates: US National Institutes of Health
Management of treatment-emergent peripheral neuropathy in multiple myeloma
PG Richardson, M Delforge, M Beksaç, P Wen, JL Jongen, O Sezer, ...
Leukemia 26 (4), 595-608, 2012
Mandates: US National Institutes of Health
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem …
A Palumbo, SV Rajkumar, JF San Miguel, A Larocca, R Niesvizky, ...
Journal of clinical oncology 32 (6), 587-600, 2014
Mandates: US National Institutes of Health
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)
EM Ocio, PG Richardson, SV Rajkumar, A Palumbo, MV Mateos, ...
Leukemia 28 (3), 525-542, 2014
Mandates: US National Institutes of Health
Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group
J Laubach, L Garderet, A Mahindra, G Gahrton, J Caers, O Sezer, ...
Leukemia 30 (5), 1005-1017, 2016
Mandates: US National Institutes of Health
IMWG consensus on maintenance therapy in multiple myeloma
H Ludwig, BGM Durie, P McCarthy, A Palumbo, J San Miguel, B Barlogie, ...
Blood, The Journal of the American Society of Hematology 119 (13), 3003-3015, 2012
Mandates: US National Institutes of Health
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple …
A Palumbo, S Bringhen, A Larocca, D Rossi, F Di Raimondo, V Magarotto, ...
Journal of Clinical Oncology 32 (7), 634-640, 2014
Mandates: Government of Italy
Publication and funding information is determined automatically by a computer program